ViewsML Closes Funding Round to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform
ViewsML announced an oversubscribed $4.9 million seed round led by Wittington Ventures, with new investors Mayo Clinic and Continuum Health Ventures joining repeat backers. The capital will fast‑track commercialization of its AI‑driven virtual biomarker staining platform, which extracts per‑cell biomarker insights from routine pathology images without laboratory staining. By converting immunohistochemistry into software, the technology reduces analysis time from days or weeks to minutes while preserving scarce tissue samples. The company will use the funds to expand strategic partnerships, advance clinical validation, and grow its engineering and commercial teams.
FMRI-Based Mega-Study of Psychedelics Reveals Patterns of Brain Signaling Reorganization
An international consortium analyzed resting‑state fMRI scans from over 250 healthy volunteers who received psilocybin, LSD, DMT, mescaline or ayahuasca, creating the largest pooled dataset of psychedelic brain imaging to date. Using a unified processing pipeline and Bayesian hierarchical modeling,...
OSK Reprogramming Restores Adult Heart Regeneration
NEW STUDY: OSK rewinds the clock and pushes adult heart cells into a regenerative state that improves heart repair Why is this such a big deal? Because adult heart cells do not meaningfully divide, which is why the heart heals with scar...
Viewpoint — ‘Completely Unethical’: RFK, Jr.’s Medical Ignorance Deprives Melanoma Cancer-Sufferers of a Life-Saving Therapy
Replimune’s RP1, a promising therapy for metastatic melanoma, received an initial FDA advisory panel recommendation for approval, but the agency’s biologics chief Vinay Prasad overruled the decision and halted the drug’s launch. At a House hearing, Health and Human Services...
Muons, Massive Waves and Restored Sight: The Winners at the ‘Oscars of Science’ – Podcast
The Breakthrough Prize, dubbed the "Oscars of science," handed out $3 million awards in physics, mathematics and life sciences at a high‑profile ceremony in Los Angeles. Jean Bennett was among the laureates, receiving the life‑sciences prize for co‑creating the first FDA‑approved gene‑augmented...
Accelerating Drug Discovery with Fragment Screening
Scientists at DOE’s Brookhaven National Laboratory are piloting a publicly‑available fragment‑based drug design (FBDD) platform at the NSLS‑II synchrotron. Using macromolecular X‑ray crystallography, the program couples robotics, automation and AI to screen small chemical fragments against protein targets. Early tests...
Crowdfunded Rapamycin‑Exercise Trial Shows Promising Aging Data
Five years ago, @BradStanfieldMD reached out with an idea: a crowdfunded clinical trial testing rapamycin combined with exercise in older adults. The results are now published — and Brad and I just sat down for a full 42-minute breakdown...
Insilico Launches First Longevity Board to Accelerate AI Aging Research
Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery https://t.co/Xd8GpDTVjW
Perth Biotech at Cutting Edge of the Future of Medicine
Syngenis, a Perth‑based biotech, is converting its research‑grade oligonucleotide lab into Australia’s first GMP‑certified facility, enabling local production of clinical‑grade DNA and RNA strands. The move could bring back roughly AUD 160 million (about US 105 million) of annual overseas GMP work, tapping into...
Genetic Bridge Links Ageing Theory to Lifespan Interventions
Dynamics of genetic and somatic trade-offs in ageing and mortality “These findings provide a genetic bridge between evolutionary theories of ageing and molecular mechanisms that can guide interventions to extend healthy lifespan.” https://t.co/HFGnELAIqH https://t.co/gAlE7D4OCh
Amyris, Wacker to Develop Precision-Fermented Ingredients for Personal Care
U.S. biotech Amyris and German specialty‑chemicals group Wacker have announced a joint effort to develop precision‑fermented, bio‑based ingredients for the personal‑care market. The collaboration follows Amyris’s recent capacity boost in Brazil, where it installed two 80 m³ fermentation lines to accelerate...
NSW Opens $96M RNA Research and Manufacturing Facility
New South Wales has launched a $96 million (≈$63 million USD) RNA research and manufacturing hub at Macquarie University’s Innovation Precinct. The state‑run facility, operated by Aurora Biosynthetics, will produce RNA‑based vaccines and therapeutics from a single site. NSW pledged an additional...
Columnless Midiprep: Pool Minipreps, Elute at Quarter Volume
Nice. Good midiprep. Gonna use this for some gene gun optimizations. All columnless, simply combining a few minipreps and eluting in ¼th volume. https://t.co/0unMuxJTIc
Nanomerics Secures US Patent Extending MET Platform Protection Into the 2040s
Nanomerics Ltd. has been granted a US patent that stretches the protection of its MET nanomedicine delivery platform into the 2040s. The filing secures the company’s core ocular and nose‑to‑brain drug pipelines and signals confidence in commercializing its nanotech‑based therapies.
Cochlear Cuts FY26 Profit Outlook to A$290‑330M Amid Weaker Demand
Cochlear Limited trimmed its fiscal 2026 underlying net profit guidance to A$290‑330 million (≈ $191‑$218 million) after flagging lower demand and a one‑point hit to gross margin. The guidance cut follows a 40.44% plunge in the company’s share price, underscoring pressure on the...
Researchers Explore New Approach to Multivirus Drug Development
Researchers at Stanford Medicine, led by Shirit Einav, are pioneering a host‑targeted antiviral strategy that disables human enzymes essential for viral replication rather than attacking the virus directly. Their recent Nature Communications paper describes a small‑molecule, RMC‑113, which halted replication...
New Clues to Hepatitis B Species Restriction Could Help Build a Novel Model for Studying Infection
Researchers at Rockefeller University discovered that mouse liver cells can generate hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) at levels similar to human cells, overturning the long‑held belief that DNA composition blocks infection. The study pinpointed a late‑stage...
Chicken Gene-Editing Advance Opens Path to Drug-Producing Eggs
University of Missouri researchers used CRISPR to insert a gene cassette into the chicken housekeeping gene GAPDH, overcoming epigenetic silencing that has hampered stable transgenic poultry. The inserted reporter stayed active for months of cell division, proving continuous expression. This...
Cosmetics From Waste? Microbial Discovery Unlocks Greener Route to High-Value Chemical Products
Researchers at the University of Toronto have identified how chain‑elongating bacteria can be coaxed to produce medium‑chain carboxylic acids (MCCAs) such as octanoic acid, a high‑value chemical used in cosmetics, surfactants and animal feed. The study, published in Nature Microbiology,...
Overlooked Brain Damage Sets Off a Chain Reaction that Could Change How Neurodegeneration Is Fought
Cambridge researchers have shown that localized damage to white‑matter myelin can provoke a cascade of changes in distant gray‑matter regions, including reduced neuronal activity, microglial activation, and loss of synaptic connections. The study, published in Nature, demonstrated that these effects...
AI Discovers Chromogranin A Shields Brains From Alzheimer’s
20 to 30% of older adults have full blown Alzheimer's pathology in their brains (plaques, tangles etc.). But they never develop symptoms and nobody knew why. An AI just read thousands of human brains and named the reason: a protein...
FDA Notification Regarding Dehydrated Alcohol
The FDA has issued a formal notice telling companies to stop distributing any dehydrated alcohol products that are not the FDA‑approved Ablysinol from Belcher Pharmaceuticals. Ablysinol, approved on June 21, 2018, is the only legally marketed dehydrated alcohol in 1 mL and 5 mL...
Paxlovid Showed No Hospitalization Benefit in Vaccinated Seniors
In 2 randomized, open-label trials of Paxlovid there was lack of evidence of reduced hospitalizations among the participants, who were age 50+ with coexisting conditions, and who were vaccinated. The endpoint was very low (<1.2%) in the treatment and control...
GDUFA III Drug Master File (DMF) Review Enhancements
The FDA’s GDUFA III reauthorization adds a mechanism for early review of Type II API drug master files up to six months before an ANDA or prior‑approval supplement is filed. A draft guidance explains how DMF holders can request a “DMF prior...
Mabwell’s Nectin‑4 ADC Shows Pseudoprogression in Cervical Cancer Case Report
Mabwell announced that a case report on its Nectin‑4‑targeting ADC 9MW2821, published in The New England Journal of Medicine, documented a rare hepatic pseudoprogression in an advanced cervical cancer patient. The report highlights dramatic tumor marker decline and lesion resolution,...
Conavi Medical Secures FDA Clearance for Hybrid IVUS‑OCT Imaging System
Conavi Medical announced that the U.S. Food and Drug Administration has cleared its next‑generation hybrid intravascular ultrasound (IVUS) and optical coherence tomography (OCT) system. The device delivers simultaneous, co‑registered imaging and advanced lesion‑stent analysis, positioning it as a potential game‑changer...
25% Beta‑Cell Loss and Aging Drive Type 2 Diabetes
Researchers analyzed ~250,000 pancreatic islet cells and found that in type 2 diabetes, about 25% of insulin-producing beta cells are lost and many of the remaining ones become aged and dysfunctional. They identified dozens of genes—along with pathways like vitamin...
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
The BioPharm Brief highlights three pivotal biopharma trends: early‑stage process design flaws can cripple cell and gene therapy scale‑up, leronlimab demonstrates early clinical and biomarker activity in metastatic colorectal cancer, and Amneal Pharmaceuticals’ acquisition of Kashiv BioSciences creates a vertically...
Creating Baby Geniuses to Thwart the AI Threat? (Yes, Really.)
A cluster of Silicon Valley billionaires—including Peter Thiel, Sam Altman, Marc Andreessen and Vitalik Buterin—are financing embryo‑editing startups that aim to prevent disease and, for some, create children capable of outthinking advanced AI. The firms, such as Nucleus, are leveraging CRISPR...
Oncology Leaders Address Testing, Access, Equity, and Pharmacy in Cancer Care
On March 12, 2026, the American Journal of Managed Care convened Chicago oncology leaders to discuss precision testing, equity, and pharmacy integration in cancer care. Panels emphasized universal biomarker testing for lung cancer, highlighted gaps such as low EGFR testing...
STAT+: At AACR, Talk of Chinese Biotech, Oncology’s Comms Issue, and More
Revolution Medicines highlighted two key updates at the AACR meeting: promising frontline pancreatic cancer data for its RAS inhibitor daraxonrasib and the introduction of a novel compound, RM-055. RM-055 is described as a catalytic inhibitor that can strip a phosphate...
Cellular Mechanisms Behind Diabetes-Derived Vascular Disease Unveiled
A study led by Zhen Chen at City of Hope uncovered that the receptor TREM2 is markedly up‑regulated in macrophages and endothelial cells of arteries from type‑2 diabetes patients, disrupting vascular repair. Using single‑cell RNA sequencing, spatial transcriptomics, and a...
An Experimental New Drug for Stiff Person Syndrome Restores Mobility
Researchers at Kyverna Therapeutics reported that a single infusion of their experimental CAR‑T cell therapy, miv‑cel, dramatically improved mobility in patients with stiff person syndrome (SPS). In a Phase II trial of 26 participants, walking speed increased and eight of twelve...
Kailera Leads, SANA Ranks #2 Among Biggest Biotech IPOs
The excellent @biospace 📊👇shows the 5 biggest IPOs in BioTech history. At the top of this list is of course Kailera Therapeutics $KLRA with its $625M blockbuster IPO - the largest public offering in recent years. The one that caught...
BioMérieux Unveils BIOFIRE SPOTFIRE Molecular Testing Solution for Biopharma
bioMérieux has launched BIOFIRE SPOTFIRE, a molecular testing system aimed at biopharma quality control. The instrument delivers mycoplasma results in less than an hour, leveraging automated workflows, touchscreen operation, and barcode scanning. Designed to be compact and stackable, it integrates with...
Andelyn Partners with S. Korea-Based ENCell to Accelerate Global Delivery of Gene Therapies
Andelyn Biosciences and South Korea’s ENCell have signed a collaboration to create a dual‑hemisphere manufacturing bridge between the United States and the Asia‑Pacific region. The agreement leverages both firms’ GMP facilities, viral vector expertise and regional networks to accelerate development,...
Ocrelizumab in PPMS. Complementing Regulatory History with a Decade of Clinical Evidence
Roche’s ocrelizumab (Ocrevus) is the only FDA‑approved disease‑modifying therapy for primary progressive multiple sclerosis (PPMS). Since its 2017 approval based on the ORATORIO trial, a decade of data—including the 2025 O’HAND study and ten‑year extension analyses—has confirmed robust efficacy across...
Pharmaceutical Executive Daily: Idvynso Receives FDA Approval
The FDA granted approval to Idvynso, a new oral therapy for HIV‑1 infection in adults, citing trial data that showed sustained viral suppression and a safety profile on par with existing regimens. The drug adds to a shifting HIV market...
Why Early Process Design Is Key to Cell and Gene Therapy Success
At INTERPHEX 2026, Charles River’s Dr. Alan Smith warned that cell and gene therapy developers often prioritize rapid first‑in‑human studies at the expense of scalable manufacturing. He highlighted recurring gaps where insufficient early‑stage process design forces costly redesigns during later trials or...
GVasc Saliva Kit Tutorial
The gVasc study released a tutorial showing how participants can collect saliva samples at home using a simple kit. Project Manager Christine Russo demonstrates the step‑by‑step process in a short video, emphasizing ease of use. gVasc, launched by cardiologists at...
10x Science: The Founders Who Built the Field Are Now Building the Platform
10x Science is launching an AI‑driven platform that automates molecular characterization of biologic drugs, a step traditionally performed manually by PhD scientists using outdated software. The company’s founders—two Stanford‑trained researchers with Nobel‑linked publications and a veteran YC entrepreneur—bring deep scientific...
Food, Not Pills, May Solve Obesity and Heart Disease
The next breakthrough in managing obesity, heart disease, or cognitive decline might not come from a pill. It might come from your food. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your...
Fenebrutinib Shows Promise, Yet Safety Concerns Loom
Relevant to $TGTX was the Roche $RHHBY fenebrutinib trial results recently announced. Excellent efficacy, but two cases of Hy's Law. Both resolved, but a patient might not be so lucky next time. Hard for me to see this gaining widespread...
FDA Clinical Trials Training Modules
The FDA’s Center for Drug Evaluation and Research has released new clinical‑trial training modules that capture the agency’s latest regulatory intelligence, emerging guidance, and real‑world compliance experience. The curriculum serves as a global benchmark, helping organizations demonstrate regulatory excellence and...
TGTX Shows Consistently Low Relapse Rates Across Trials
This very low relapse rate in this $TGTX Phase IV observational trial is consistent with that seen in their 6-year extension study: https://t.co/Shvb8h8VRr
Top Protein Degrader Session at AACR26 Highlights Await
Excellent protein degrader session today at #AACR26. Third speaker was all Do Not Post (sorry @HartungIngo !) so some highlights from the other three speakers coming up...
Study Finds Rapamycin May Undermine Exercise Gains in Seniors
An international team led by Brad Stanfield reported that a weekly 6 mg dose of rapamycin blunted the functional gains from a 13‑week home exercise program in 40 sedentary adults aged 65‑85. The placebo group outperformed the rapamycin group on chair‑stand,...
Alzheimer's Drugs Show Minimal Benefit, Review Reveals Deeper Issues
Alzheimer’s drugs offer little benefit, major review finds – and the reasons go deeper than the science https://t.co/cnMPAEQumY https://t.co/wtg8llquON
FDA Criticizes Replimune's Melanoma Trial Design
Some observers, including @US_FDA, have criticized @Replimune for the design of the trial that led to the decision not to grant accelerated approval of their melanoma treatment. I asked the company's Chairman about that view. Watch the full interview: https://t.co/XYVmSeodLv https://t.co/OO8eXTZOXh
Dayspring Pharma’s CG2001 Foam Hits Primary Endpoint in Phase II AGA Trial of 110 Chinese Men
Dayspring Pharma announced that its CG2001 foam achieved the primary efficacy endpoint in a 30‑week Phase II study of 110 Chinese men with androgenetic alopecia. The combination of 5% minoxidil and 0.075% finasteride delivered roughly 50% greater hair‑growth results versus historic...